Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Alternative RNA Splicing

Alternative RNA Splicing

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

Pre-mRNA Processing: RNA Splicing

Pre-mRNA Processing: RNA Splicing

Point and Frameshift Mutations

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Nature communications·2026

Same author

Long-read cDNA sequencing reveals novel isoforms and spliceosome-mutant-enriched transcripts in AML and MDS.

bioRxiv : the preprint server for biology·2026

Same author

U2af1<sup>S34F</sup> and U2af1<sup>Q157R</sup> myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.

Leukemia·2026

Same author

Nonsense-Mediated RNA Decay is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-loop Accumulation and DNA Damage.

Cancer research·2026

Same author

Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.

Science (New York, N.Y.)·2026

Same author

Modeling the evolutionary dynamics of clonal hematopoiesis.

Nature genetics·2026

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 10, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Splicing factor gene mutations in hematologic malignancies.

Borja Saez^1,2, Matthew J Walter³, Timothy A Graubert¹

¹Massachusetts General Hospital Cancer Center, Boston, MA.

|December 13, 2016

Summary

This summary is machine-generated.

Splicing factor mutations are key drivers in myeloid cancers and clonal hematopoiesis, initiating disease and altering blood cell development. These mutations offer potential therapeutic targets for novel cancer treatments.

More Related Videos

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Experiment Videos

Last Updated: Mar 10, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Area of Science:

Molecular Biology
Oncology
Genetics

Background:

Alternative splicing generates diverse messenger RNA (mRNA) transcripts, increasing proteome complexity.
Splicing processes are frequently disrupted in cancer, particularly in hematologic malignancies.
Recurrent mutations in splicing factors are recognized as a hallmark of myeloid cancers.

Purpose of the Study:

To review recent advancements in understanding splicing factor mutations in cancer.
To emphasize clinical consequences and mechanistic insights from animal models.
To explore implications for developing novel therapies targeting mRNA splicing.

Main Methods:

Review of current scientific literature on splicing factor mutations.
Analysis of clinical data and patient outcomes related to these mutations.
Examination of findings from animal models investigating splicing factor roles.

Main Results:

Splicing factor mutations are early events in myeloid cancer development.
These mutations are also found in healthy elderly individuals with clonal hematopoiesis, indicating a role in disease initiation.
Mutations alter splicing patterns in hematopoietic cells and affect differentiation and maturation in animal models.

Conclusions:

Splicing factor mutations are critical in the initiation and progression of hematologic malignancies.
Understanding these mutations provides mechanistic insights into cancer development.
Targeting the precursor mRNA splicing pathway presents a promising avenue for novel cancer therapies.